Skip to main content
Premium Trial:

Request an Annual Quote

Mary Schramke, Kevin Corcoran, Susan Desmond-Hellmann, Larry Kleinman, Charles Kalmbach, Theo Melas-Kyriazi, Elliot Sigal, Gary Noon, Bob Beltz, Pedro Granadillo, Andras Guttman

Mary Schramke was named acting chief executive officer for Lynx Therapeutics effective Dec. 15, the company said this week. She succeeds Kevin Corcoran who resigned as president, CEO, and director to pursue another business opportunity, the company said. Schramke previously was vice president of business development for Lynx, where she has worked since 2003.


Susan Desmond-Hellmann has been named to the board of directors of Affymetrix, the company said this week. Desmond-Hellman oversees regulatory affairs, medical affairs, product development and other functions for Genentech.


Larry Kleinman joins New York-based outplacement firm DBM as executive vice president of human performance, the company said this week. He will report to Charles Kalmbach, CEO. Previously, Kleinman was senior vice president and chief human resources officer at New World Pasta, and before that he was VP for global human resources for the Campbell’s Soup Company. He has worked at Nabisco, Becton Dickinson, General Electric, and GTE.


Theo Melas-Kyriazi, former CFO of Thermo Electron, joins the board of directors of Cyberkinetics Neurotechnology Systems. Since joining Thermo in 1986, Melas-Kyriazi held various management positions including president and CEO of Thermo Spectra, a Thermo subsidiary he took through its IPO and subsequent significant growth. He resigned from Thermo on Oct. 1.


James Palmer, chief scientific officer and president of the Pharmaceutical Research Institute, died while undergoing surgery recently, Bristol-Myers Squibb announced. Elliot Sigal, senior vice president of global clinical and pharmaceutical development for Bristol-Myers, becomes acting president of the PRI.


Gary Noon has been appointed senior vice president for pharmaceuticals at Diversa. He was formerly at IMS Health, having previously held positions at Pfizer/Warner-Lambert, GlaxoWellcome and BMS.


Bob Beltz has joined MFIC as marketing manager for the company’s microfluidics division. He will lead the market introduction of the company’s new, patented, high-pressure multiple stream mixer reactor for the continuous creation of nanoparticles.


Pedro Granadillo joined the board of directors of Noven Pharmaceuticals, the Miami-based company said last week. Granadillo previously was senior vice president for global manufacturing and human resources for Eli Lilly.


Andras Guttman has joined the scientific advisory board of Irvine, Calif-based eGene, the company said recently. Guttman leads the Horvath Laboratory of Bioseparation Sciences at the University of Innsbruck, Austria. The institute pursues research in bioseparation for application in genomics, proteomics, and metabolomics. Guttman previously held appointments at Diversa, Torrey Mesa Research Institute, Genetic BioSystems, and at Beckman Coulter.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.